Attovia Therapeutics (Nasdaq: ATTO) closed its upsized initial public offering of 19,550,000 common shares, including the underwriters’ full option for 2,550,000 additional shares, at $17.00 per share. According to Attovia, the offering generated approximately $332.4 million in gross proceeds before underwriting discounts, commissions, and expenses, with all shares sold by the company.
Attovia’s stock began trading on the Nasdaq Global Market on August 5, 2026 under the symbol “ATTO.” Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets were joint book‑running managers, and LifeSci Capital acted as passive book‑running manager. The SEC declared the registration statement effective on August 4, 2026.
Loading...
Loading translation...
Positive
Gross IPO proceeds of approximately $332.4 million before expenses
19,550,000 shares sold, including full exercise of 2,550,000‑share option
All IPO shares were primary shares sold by Attovia
Shares listed on the Nasdaq Global Market under symbol ATTO
Negative
Issuance of 19,550,000 new shares creates equity dilution for existing shareholders
Net proceeds will be lower than $332.4 million after underwriting discounts and offering expenses
News Explained
The completed IPO added 19,550,000 Attovia common shares sold by the company and generated approximately $332.4 million in gross proceeds before costs; because issuing shares increases the total count, existing holders’ percentage ownership is reduced absent offsetting changes.
Market Context
ATTO's low short positioning provides limited evidence of squeeze-related positioning around the off...
Analysis
ATTO's low short positioning provides limited evidence of squeeze-related positioning around the offering. The platform record adds a dilution consideration, while future disclosures would clarify capital deployment.
Key Figures
IPO shares:19,550,000 sharesAdditional shares:2,550,000 sharesIPO price:$17.00 per share+3 more
6 metrics
IPO shares19,550,000 sharesInitial public offering
Additional shares2,550,000 sharesUnderwriters’ option exercised in full
IPO price$17.00 per shareInitial public offering
Gross proceeds$332.4 millionBefore underwriting discounts, commissions and offering expenses
Nasdaq trading startAugust 5, 2026Common stock began trading under ATTO
Registration effectivenessAugust 4, 2026Registration statement declared effective by the SEC
Key Terms
initial public offering, gross proceeds, registration statement, prospectus
4 terms
initial public offeringfinancial
"closing of its upsized initial public offering of 19,550,000 shares"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
gross proceedsfinancial
"The aggregate gross proceeds to Attovia from the initial public offering"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
registration statementregulatory
"A registration statement relating to the securities issued and sold"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
prospectusregulatory
"A prospectus relating to and describing the terms of the initial public offering"
A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the closing of its upsized initial public offering of 19,550,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,550,000 additional shares, at the initial public offering price of $17.00 per share. The aggregate gross proceeds to Attovia from the initial public offering were approximately $332.4 million, before deducting underwriting discounts and commissions and other offering expenses.All of the shares were offered by Attovia.Attovia’s common stock began trading on the Nasdaq Global Market on August 5, 2026, under the symbol “ATTO.”
Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets acted as joint book-running managers for the offering. LifeSci Capital acted as a passive book-running manager for the offering.
A registration statement relating to the securities issued and sold in the initial public offering has been filed with the Securities and Exchange Commission (the “SEC”) and was declared effective on August 4, 2026. A prospectus relating to and describing the terms of the initial public offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105 or by email at syndicate@leerink.com; Citigroup Global Markets, Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146; and RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at 1-877-822-4089 or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Attovia, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Attovia Therapeutics, Inc.
Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using our ATTOBODY biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process which allows for rapid discovery and creation of a high diversity of potential product candidates.
Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases, ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.
Investor and Media Contact PJ Kelleher LifeSci Advisors 617-430-7579 pkelleher@lifesciadvisors.com
FAQ
How much did Attovia Therapeutics (NASDAQ: ATTO) raise in its August 2026 IPO?
Attovia raised approximately $332.4 million in gross proceeds from its IPO. According to Attovia, this amount reflects 19,550,000 shares sold at $17.00 per share, before underwriting discounts, commissions, and other offering expenses that reduce net proceeds.
How many shares did Attovia Therapeutics (ATTO) sell in its upsized IPO?
Attovia sold 19,550,000 shares of common stock in its IPO. According to Attovia, this total includes 2,550,000 additional shares issued after underwriters fully exercised their option, with all shares offered directly by the company rather than existing shareholders.
What was the IPO price for Attovia Therapeutics (NASDAQ: ATTO) and when did trading start?
Attovia priced its IPO at $17.00 per share, with trading starting August 5, 2026. According to Attovia, its common stock is listed on the Nasdaq Global Market under the ticker symbol ATTO following SEC effectiveness of the registration statement.
Did underwriters fully exercise their option to buy additional Attovia (ATTO) shares in the IPO?
Yes, underwriters fully exercised their option to purchase 2,550,000 additional shares. According to Attovia, these option shares are included in the total 19,550,000 shares sold in the offering, all issued by the company at the $17.00 IPO price.
Who were the underwriters for the Attovia Therapeutics (ATTO) IPO in August 2026?
Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets were joint book‑running managers. According to Attovia, LifeSci Capital served as a passive book‑running manager, supporting the distribution of shares priced at $17.00 each on the Nasdaq Global Market.
When did the SEC declare Attovia Therapeutics’ (ATTO) IPO registration statement effective?
The SEC declared Attovia’s IPO registration statement effective on August 4, 2026. According to Attovia, the offering was conducted only by means of a filed prospectus, which describes the IPO terms and is available through the SEC’s website and underwriter contacts.
